PE20141479A1 - Senuelos humanos notch1 - Google Patents

Senuelos humanos notch1

Info

Publication number
PE20141479A1
PE20141479A1 PE2014000473A PE2014000473A PE20141479A1 PE 20141479 A1 PE20141479 A1 PE 20141479A1 PE 2014000473 A PE2014000473 A PE 2014000473A PE 2014000473 A PE2014000473 A PE 2014000473A PE 20141479 A1 PE20141479 A1 PE 20141479A1
Authority
PE
Peru
Prior art keywords
human
sequence
fusion protein
amino acids
notch1
Prior art date
Application number
PE2014000473A
Other languages
English (en)
Inventor
Jan Kitajewski
Carrie Shawber
Thaned Kangsamaksin
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141479(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of PE20141479A1 publication Critical patent/PE20141479A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA PROTEINA DE FUSION QUE COMPRENDE LA SECUENCIA DE LA CUAL AMINOACIDOS CONSECUTIVOS, COMENZANDO EN EL EXTREMO N-TERMINAL DE LA PROTEINA DE FUSION, ES IDENTICA A LA SECUENCIA DE AMINOACIDOS EN: A) UN DOMINIO EXTRACELULAR DE UNA PROTEINA DE RECEPTOR NOTCH1 HUMANO; SEGUIDO POR B) UNA PORCION FC DE UN ANTICUERPO; EN DONDE EL DOMINIO EXTRACELULAR DE LA PROTEINA HUMANA DEL RECEPTOR NOTCH1 i) COMIENZA CON EL AMINOACIDO PRESENTE EN EL EXTREMO N-TERMINAL DE LA REPETICION TIPO EGF 10, Y ii) SE EXTIENDE AL MENOS A TRAVES DEL AMINOACIDO EN EL C-TERMINAL DE REPETICION TIPO EGF 23. DICHA SECUENCIA DE AMINOACIDOS CONSECUTIVOS DE LA PROTEINA DE FUSION COMPRENDE LA SECUENCIA DE SEQ ID N�: 3 O 5. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA PARA INHIBIR LA ACTIVIDAD DE JAGGED-1 SIENDO UTIL EN EL TRATAMIENTO DE DEGENERACION MACULAR RELACIONADA CON LA EDAD, RETINOPATIA DIABETICA, CANCER
PE2014000473A 2011-10-04 2012-10-04 Senuelos humanos notch1 PE20141479A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161543186P 2011-10-04 2011-10-04

Publications (1)

Publication Number Publication Date
PE20141479A1 true PE20141479A1 (es) 2014-11-05

Family

ID=48044136

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000473A PE20141479A1 (es) 2011-10-04 2012-10-04 Senuelos humanos notch1

Country Status (19)

Country Link
US (2) US9738708B2 (es)
EP (1) EP2763700A4 (es)
JP (1) JP2014532061A (es)
KR (1) KR20140093942A (es)
CN (1) CN103917247A (es)
AR (1) AR088048A1 (es)
AU (1) AU2012318664A1 (es)
BR (1) BR112014008025A2 (es)
CA (1) CA2850944A1 (es)
CL (1) CL2014000852A1 (es)
HK (1) HK1198427A1 (es)
IL (1) IL231920A0 (es)
MX (1) MX2014004132A (es)
PE (1) PE20141479A1 (es)
RU (1) RU2014117160A (es)
SG (1) SG11201401186RA (es)
TW (1) TW201329105A (es)
WO (1) WO2013052607A1 (es)
ZA (1) ZA201403044B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
KR20100076947A (ko) 2007-08-23 2010-07-06 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 인간화 노치 융합 단백질 조성물 및 치료방법
SG193873A1 (en) 2008-08-22 2013-10-30 Univ Columbia Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
TW201329105A (zh) * 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
WO2017205651A1 (en) * 2016-05-25 2017-11-30 The Trustees Of Columbia University In The City Of New York Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling
WO2023192802A1 (en) * 2022-04-01 2023-10-05 The Board Of Trustees Of The University Of Illinois Notch1 and notch4 decoys and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
FR2751986B1 (fr) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
JP2005526701A (ja) 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
JP2006506322A (ja) 2002-04-05 2006-02-23 ロランティス リミテッド 内科療法
AU2003255735A1 (en) 2002-08-03 2004-02-23 Lorantis Limited Conjugate of notch signalling pathway modulators and their use in medical treatment
JP2006515177A (ja) 2002-09-10 2006-05-25 ロランティス リミテッド Ｎｏｔｃｈリガンドタンパク質を含む医薬組成物及び医学的処置
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
WO2006047878A1 (en) 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
WO2007016419A2 (en) 2005-07-29 2007-02-08 The General Hospital Corporation Methods and compositions for reducing skin damage
KR101525629B1 (ko) 2006-10-19 2015-06-26 제넨테크, 인크. 항-Ｎｏｔｃｈ3 작동제 항체 및 Ｎｏｔｃｈ3 관련 질환을 치료하는 데에 있어서의 그의 용도
JP5618544B2 (ja) * 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
KR20100076947A (ko) * 2007-08-23 2010-07-06 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 인간화 노치 융합 단백질 조성물 및 치료방법
AU2009269095B2 (en) * 2008-07-08 2016-05-19 Oncomed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
SG193873A1 (en) 2008-08-22 2013-10-30 Univ Columbia Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
TW201329105A (zh) * 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物

Also Published As

Publication number Publication date
CA2850944A1 (en) 2013-04-11
AU2012318664A1 (en) 2014-05-22
US9738708B2 (en) 2017-08-22
AR088048A1 (es) 2014-05-07
SG11201401186RA (en) 2014-04-28
US20140271643A1 (en) 2014-09-18
MX2014004132A (es) 2014-07-24
EP2763700A1 (en) 2014-08-13
US20170306006A1 (en) 2017-10-26
KR20140093942A (ko) 2014-07-29
WO2013052607A9 (en) 2014-04-10
US10227399B2 (en) 2019-03-12
ZA201403044B (en) 2016-01-27
RU2014117160A (ru) 2015-11-10
JP2014532061A (ja) 2014-12-04
CN103917247A (zh) 2014-07-09
WO2013052607A1 (en) 2013-04-11
HK1198427A1 (en) 2015-04-24
EP2763700A4 (en) 2015-05-27
BR112014008025A2 (pt) 2017-04-11
IL231920A0 (en) 2014-05-28
TW201329105A (zh) 2013-07-16
CL2014000852A1 (es) 2014-12-12

Similar Documents

Publication Publication Date Title
PE20141479A1 (es) Senuelos humanos notch1
CL2017002761A1 (es) Proteínas de fusión
CO6220870A2 (es) Prediccion de respuesta a un inhibidor a un inhibidor de dimerizacion her basado en expresion de her3 bajo
PE20141561A1 (es) Anticuerpos anti-lrp5 y metodos de uso
AR079333A1 (es) Anticuerpos contra csf -1r humano y usos de los mimos
CL2017001379A1 (es) Composiciones anti-cgrp y uso de las mismas (solicitud divisional 3336-2013)
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
ES2676499T3 (es) Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
UY33204A (es) Metodos y composiciones usando polipeptidos de fusion de fgf23
PE20171058A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
GT201200058A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
PE20141551A1 (es) Proteinas de fusion para tratar trastornos metabolicos
BR112015022978A8 (pt) tecnologias de multimerização
PE20130199A1 (es) Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
PE20142168A1 (es) Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
ES2633597T3 (es) Anticuerpos con afinidad modificada para FcRn que promueven la eliminación del antígeno
PE20190743A1 (es) Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib
CU20120116A7 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5

Legal Events

Date Code Title Description
FD Application declared void or lapsed